Showing 143 Results
Spending on Phased Clinical Development of Approved Drugs by the US National Institutes of Health Compared With Industry
New study examines the role of NIH and industry in bringing new treatments into clinical settings.
NPC Comments on Proposed Changes for ICER Value Assessment Framework
NPC's comments highlight key concerns related to proposed changes to ICER's 2023 Value Assessment Framework.
NPC Comments on CMS' Drug Price Negotiation Counteroffer Information Collection Request
As CMS develops the detailed steps involved in the agency's drug pricing processes, NPC's comments highlight key shortcomings in the agency's counteroffer information collection request (ICR).
NPC Comments on CMS Information Collection Request for Negotiation Data Elements
NPC's comments offer input on the agency's latest efforts to implement the drug price-setting provisions of the Inflation Reduction Act through the design of a data collection process.
NPC Comments on CMS Medicare Drug Price Negotiation Program
NPC's comments highlight concerns about the agency's guidance regarding the implementation of Medicare Drug Price Negotiation and the potential for unintended consequences, including less…
The President’s victory lap on the success of price controls is premature
In a commentary published in the Sarasota Herald-Tribune, NPC's John M. O’Brien discusses the potential effects of new price controls and what the future holds for Medicare.
Innovating to Help Patients with Rare Diseases
One out of every 10 Americans live with a rare disease. Rare Disease Day serves as a reminder of their many needs and challenges and the work that researchers, clinicians, and our member companies do…
Good Health Policy Requires High-Quality Evidence
In health policy debates, honest, realistic and evidence-based discussions are foundational.
Characterizing Health Plan Evidence Review Practices
The study finds that some plans updated the evidence in their coverage policies for specialty medicines more often than others, and the type of evidence plans cited in their coverage policies…
Characterizing health plan evidence review practices: how often, how different, and how comprehensive?
All health care decisions should be evidence-based. Until now, it has been relatively unclear what goes into health plan evidence reviews. How frequently do health plans update their specialty drug…
An Oversimplified Drug Price Policy That Misses the Point
Drug price controls have a range of downstream consequences for the biopharmaceutical market and, more importantly, for patients.
The Impact of Price Regulation on Innovation: What the Research Shows
Potential drug price controls have a range of downstream consequences for the biopharmaceutical market and, more importantly, for patients.
NPC’s John O’Brien Discusses March-in, Co-pays, and Patient Access
On a recent episode of VITAL HEALTH podcast, John M. O’Brien discusses the health care ecosystem and the importance of fostering biopharmaceutical innovation and improving patient access.
Health Care Spending Effectiveness: Estimates Suggest that Spending Improved U.S. Health from 1996 to 2016
This research assessed the effectiveness of U.S. health care spending by comparing changes in health outcomes and found that, overall, innovations in health care are creating more cost-effective care…
Health Care Spending Guiding Principles
NPC established a set of principles to assess health care spending estimates and policies to ensure alignment with the goals of patient-centered care.
Patient-Centered Guiding Principles for Evaluating Health Care Spending
NPC established these principles to serve as a checklist to assess whether methods used for estimating health care spending are appropriate.
Patient-Centered Guiding Principles for Reforming Health Care to Address Rising Health Care Spending
NPC established these principles to assess health care spending policies to ensure alignment with the goals of patient-centered care.
Innovation Matters: Changing Lives for Cystic Fibrosis Patients
In this video from NPC’s Innovation Matters series, cystic fibrosis patient advocate Katherine Fielding discusses how the invention of modulator therapies has changed her life and how more innovation…